BeOne Medicines Ltd. Class A

As of June 30, 2026, BeOne Medicines Ltd. Class A carries a market capitalization of 374.21B, placing it among publicly traded companies globally. Its enterprise value stands at 347.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BeOne Medicines Ltd. Class A's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, BeOne Medicines Ltd. Class A has 1.47B shares outstanding.

As of June 30, 2026, BeOne Medicines Ltd. Class A trades at a trailing price-to-earnings ratio of 82.49. The price-to-sales ratio is 8.83, and the price-to-book ratio stands at 10.66.

As of June 30, 2026, BeOne Medicines Ltd. Class A trades at an EV/EBITDA multiple of 47.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 55.47 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BeOne Medicines Ltd. Class A trades at an EV/FCF ratio of 37.54, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 347.37B versus a market cap of 374.21B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BeOne Medicines Ltd. Class A maintains a current ratio of 3.40, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.10, indicating elevated leverage, while an interest coverage ratio of 14.84 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. Class A posted a return on equity (ROE) of 14.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.18 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.79, useful for judging operating efficiency across full business cycles. The company generates approximately 3.54M in revenue per employee across its workforce of 11,750.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.10 indicates how many times BeOne Medicines Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. Class A recorded 1.44B in income tax expense. That works out to an effective tax rate of 24.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.89B, leaving 4.45B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BeOne Medicines Ltd. Class A's stock has declined approximately 6.12% over the past 52 weeks. The 50-day moving average sits at 268.45, while the 200-day moving average is 258.59.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. Class A generated 41.58B in revenue and converted that into 4.45B in net income, yielding earnings per share of 2.97. EBITDA reached 7.31B, while operating income came in at 6.26B.

As of June 30, 2026, BeOne Medicines Ltd. Class A holds 34.59B in cash and equivalents against 7.76B in total debt, resulting in a net debt position of -27.31B. Total book value stands at 35.10B, with working capital of 34.58B providing operational flexibility.

BeOne Medicines Ltd. Class A produced 10.07B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.19B in capital expenditures, free cash flow totaled 8.88B - equivalent to 6.16 per share.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. Class A posted a gross margin of 88.89, reflecting its pricing power and cost economics. The operating margin of 15.06 and net profit margin of 10.70 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.33, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -2.03, meaning BeOne Medicines Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BeOne Medicines Ltd. Class A has an Altman Z-Score of 8.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.